Abstract Body

Data addressing aging’s effects on T cell phenotype suggest that age blunts CD4 cell count (CD4) improvements observed with ART-induced viral suppression. Prolonged viral suppression reduces immune activation, reflected by a rising CD4/CD8 ratio (T4/T8). We studied T4/T8 over time to determine whether it could predict risk for select comorbidities or mortality among aging persons with HIV (PWH) and ≥1year (y) virologic control.

We analyzed data from HIV Outpatient Study (HOPS) participants (ppts) seen at 12 U.S. HIV clinics who were followed from 2000-2018 with known baseline CD4, ART initiation date, all viral loads (VL) <200 copies/mL during 1st observation y, ≥1y of follow up with ≥2 T4/T8 measures. We analyzed T4/T8 <0.7 by age group. Cochran-Armitage trend tests were used to compare proportions across time, and by baseline age. Clinical outcomes included any cancer, dyslipidemia and all-cause mortality. Case-control analyses were performed using conditional logistic regression (CLR) to assess for associations of T4/T8 with outcomes matching 1:1 for smoking, hepatitis C, nadir CD4, race/ethnicity, sex and insurance, with age as an independent variable.

1,910 ppts were included. Median follow up was 7.2y. At date of first VL <200 copies/mL, 908 (46%) were <40y, 626 (33%) 40-49y, and 376 (20%) ≥50y; 82% male; 50% Non-Hispanic (NH) white, 34% NH black, and 12% Hispanic; 62% were on their 1stART regimen, 20% on their ≥4thregimen; 38% had a nadir CD4 <200 cells/mm3. Baseline T4/T8 was 0.3 (interquartile range: 0.2-0.6), not statistically different for the 3 age groups. T4/T8 increases by baseline age differed through 4y of follow up (P<0.001 for each year). Over time, the percentage of ppts with T4/T8 ≥0.7 increased for all ages, but less among 40-49y and ≥50y than <40y group (Figure). In clinical outcomes analyses (n=77 deaths, n=167 cancer, and n=461 dyslipidemia) using CLR, accounting for age, T4/T8 <0.7 at last measurement was associated with mortality (Odds Ratio [OR] 2.96, 95% Confidence Interval [CI] 1.30-6.74), cancer (OR 1.83, CI 1.11-3.02), and dyslipidemia (OR 4.02, CI 2.90-5.58).

Pre-treatment immune injury may persist as assessed by T4/T8 which may not resolve even with prolonged viral suppression and may have clinical consequences in aging PWH